Porustobart - Harbour BioMed
Alternative Names: HBM-4003; HCAb-4003-2Latest Information Update: 28 Apr 2024
At a glance
- Originator Harbour BioMed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer; Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
- Phase I/II Malignant melanoma
- Phase I Non-small cell lung cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease) in China (IV)
- 02 Jun 2023 Adverse events, efficacy and pharmacodynamics data from a phase Ib trial in solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 26 May 2023 Efficacy, pharmacokinetics and adverse events data from a phase Ib trial in Hepatocellular carcinoma released by Harbour BioMed